(3) The above-mentioned solution (2) was added to the above-mentioned solution (1) with stirring, and they were mixed. A flavor was further added and they were mixed.

(4) 1N Aqueous sodium hydroxide solution was added to the above-mentioned solution (3) to adjust pH to 3.0-3.2, and diluted with purified water to the final concentration. The mixture was filtered with a stainless steel screen to give an aqueous solution for oral administration having the composition of Table 1.

[0027]

Table 1

component	quantity (mg/mL)
compound (I)	1
polyethylene glycol 400	100
propylene glycol	50
DL-lactic acid *	15.01
methylparaben	1
propylparaben	0.2
edetate disodium **	0.1
glycine	10
sucralose	0.75
stevia	0.6
flavor	0.9
1N aqueous sodium hydroxide solution	q.s.
purified water	q.s.

*: DL-lactic acid used was of content 90.0%, which is about 13.5 mg/mL when converted to DL-lactic acid as content 100%. The same applies to the following Examples and Control Examples.

**: Edetate disodium used was ~~dehydrate~~dihydrate ($C_{10}H_{14}N_2Na_2O_8$ $2H_2O$). The same applies to the following Examples and Control Examples.

[0028]

Example 1-2

(1) Polyethylene glycol 400 and a part (20 - 30%) of purified water were mixed, compound (I) was added and dispersed with stirring. DL-lactic acid was added to this solution with

CLAIMS

1. A solution for oral administration ~~comprising~~ having pH 2.5 - 4.5, which comprises 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and at least one compound selected from the group consisting of lactic acid, phosphoric acid, glycolic acid, malic acid, tartaric acid, citric acid, succinic acid and acetic acid~~, and having pH 2.5 - 4.5~~.

2. The solution according to claim 1, further comprising glycine.

3. The solution according to claim 1 or 2, wherein at least one compound selected from the group consisting of lactic acid, phosphoric acid, glycolic acid, malic acid, tartaric acid, citric acid, succinic acid and acetic acid is lactic acid.

4. The solution according to any of claims 1 to 3, further comprising at least one flavor enhancing and/or masking agent.

5. The solution according to claim 4, wherein the enhancing and/or masking agent is sucralose.

~~5~~6. The solution according to any of claims 1 to ~~4~~5, further comprising a solubilizing agent.

7. The solution according to claim 6, wherein the solubilizing agent is propylene glycol and/or glycerin.

8. The solution according to any of claims 1 to 7, further comprising a preservative and a stabilizer.

9. The solution according to any of claims 2 to 8, wherein the content of glycine is 5 - 20 mg/mL.

10. The solution according to any of claims 3 to 9, wherein the content of lactic acid is 5 - 20 mg/mL.

11. The solution according to any of claims 3 to 9, wherein the weight ratio of glycine:lactic acid is 1:0.5 - 2.

12. The solution according to any of claims 7 to 11, wherein the solubilizing agent is composed of propylene glycol and glycerin at a weight ratio of propylene glycol:glycerin of 1:3.

13. The solution according to any of claims 1 to 12, wherein the pH is 3.0 - 3.4.

14. Composition for oral administration comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and at least one compound selected from the group consisting of lactic acid, phosphoric acid, glycolic acid, malic acid, tartaric acid, citric acid, succinic acid and acetic acid, and having pH 2.5 - 4.5 for use in a method of treating central neurological diseases.